Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

51.94 +3.01 (+6.15%)
Streaming Delayed Price Updated: 9:58 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
35 36 Next >
News headline image
2 Top Healthcare Stocks to Buy for the Long Haul ↗
These biotech companies have a long ramp of revenue growth ahead. 
Via The Motley Fool
News headline image
My Best Stocks to Buy Now and Hold Forever ↗
These are ideal "forever" stocks. 
Via The Motley Fool
News headline image
Missed Out On Axsome Therapeutics? My Best Biotech Stock to Buy and Hold ↗
Vertex already generates billions in revenue -- but there may be more to come. 
Via The Motley Fool
News headline image
What 7 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
Analysts have provided the following ratings for CRISPR Therapeutics (NASDAQ:CRSP) within the last quarter: 
Via Benzinga
News headline image
These 7 Biotech Stocks Are Set to Boom in 2023 ↗
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023 
Via InvestorPlace
News headline image
2 Cathie Wood Stocks That Are Beating the Market This Year ↗
One is doing much better than the other year to date, but they both have solid prospects ahead. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Vertex Shares Higher On Optimism About CRISPR Partnership
Shares of Vertex Pharmaceuticals are moving higher on news that regulators gave the company the go-ahead to on the review process for gene-editing treatments. 
Via MarketBeat
News headline image
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future ↗
Bluebird Bio Inc (NASDAQ: BLUE) is about to become the seller of the two most expensive drugs in the U.S. and probably the world. The price tag of $3 million is already facing backlash. 
Via Benzinga
News headline image
Vertex, Gene-Editing Leader, Heads 5 Resilient Stocks In Bear Market ↗
Vertex flashed a buy signal on positive gene-editing news. 
Via Investor's Business Daily
News headline image
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review ↗
The major indexes fell, with the S&P 500 breaking below bear market lows. 
Via Investor's Business Daily
News headline image
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders ↗
MaxCyte Inc (NASDAQ: MXCT) has signed a  
Via Benzinga
News headline image
What Is Going on With Grom Social (GROM) Stock Today? ↗
Grom Social (GROM) stock is heading higher on Tuesday following news of Chelsea and Matt Giegerich signing a deal with Curiosity Ink Media. 
Via InvestorPlace
News headline image
Why Are Crypto Mining Stocks RIOT, MARA, HUT Up Today? ↗
Crypto mining stocks are on the move Tuesday as investors react to Bitcoin (BTC) breaking past the $20,000 price point today! 
Via InvestorPlace
News headline image
Why Is Crispr Therapeutics (CRSP) Stock Up Today? ↗
Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review. 
Via InvestorPlace
News headline image
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug ↗
Crispr and Vertex nailed down the timeline for their blood diseases gene editor. 
Via Investor's Business Daily
News headline image
Why CRISPR Therapeutics Stock Is Rising Today ↗
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced the U.S. 
Via Benzinga
News headline image
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market ↗
Eli Lilly leads medical stocks setting up and showing relative strength. 
Via Investor's Business Daily
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,700 Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 20.85% on an annualized basis producing an average annual return of 29.91%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
News headline image
No One Told These 3 Stocks It’s a Down Week
At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space. 
Via MarketBeat
Topics Economy Electric Vehicles
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
Neurocrine Leads 5 Stocks To Watch In Sickly Market ↗
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
News headline image
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today ↗
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
5 Top Stocks Cathie Wood Is Selling This Week ↗
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling. 
Via InvestorPlace
News headline image
5 Cathie Wood Stocks Signaling “The Bear Market Is Over” ↗
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit. 
Via InvestorPlace
News headline image
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock ↗
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile. 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,900 Today ↗
  CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 31.2%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
News headline image
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022 ↗
  
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.